These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 11884870)

  • 1. Is pharmacologic vitreolysis brewing?
    Sebag J
    Retina; 2002 Feb; 22(1):1-3. PubMed ID: 11884870
    [No Abstract]   [Full Text] [Related]  

  • 2. Pharmacologic vitreolysis.
    Sebag J
    Retina; 1998; 18(1):1-3. PubMed ID: 9502274
    [No Abstract]   [Full Text] [Related]  

  • 3. Hyaluronidase for pharmacologic vitreolysis.
    Narayanan R; Kuppermann BD
    Dev Ophthalmol; 2009; 44():20-25. PubMed ID: 19494648
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacologic vitreolysis.
    Gandorfer A
    Dev Ophthalmol; 2007; 39():149-156. PubMed ID: 17245084
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacologic vitreolysis.
    Rhéaume MA; Vavvas D
    Semin Ophthalmol; 2010; 25(5-6):295-302. PubMed ID: 21091015
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anticipation for enzymatic vitreolysis.
    Bhisitkul RB
    Br J Ophthalmol; 2001 Jan; 85(1):1-2. PubMed ID: 11133700
    [No Abstract]   [Full Text] [Related]  

  • 7. Molecular biology of pharmacologic vitreolysis.
    Sebag J
    Trans Am Ophthalmol Soc; 2005; 103():473-94. PubMed ID: 17057814
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Microplasmin for vitreomacular traction.
    Udaondo P; Diaz-Llopis M; Garcia-Delpech S; Salom D; Arevalo JF
    Ophthalmology; 2010 Sep; 117(9):1859, 1859.e1; author reply 1859-60. PubMed ID: 20816250
    [No Abstract]   [Full Text] [Related]  

  • 9. Pharmacologic vitreolysis--premise and promise of the first decade.
    Sebag J
    Retina; 2009; 29(7):871-4. PubMed ID: 19584647
    [No Abstract]   [Full Text] [Related]  

  • 10. Pathology of Internal Limiting Membrane Specimens Following Intravitreal Injection of Ocriplasmin.
    Schumann RG; Wolf A; Mayer WJ; Compera D; Hagenau F; Ziada J; Kampik A; Haritoglou C
    Am J Ophthalmol; 2015 Oct; 160(4):767-78. PubMed ID: 26133247
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute ocriplasmin retinopathy.
    Johnson MW; Fahim AT; Rao RC
    Retina; 2015 Jun; 35(6):1055-8. PubMed ID: 25996428
    [No Abstract]   [Full Text] [Related]  

  • 12. Pharmacologic vitreolysis: rationale, potential indications, and promising agents.
    Gandorfer A
    Retina; 2012 Sep; 32 Suppl 2():S221-4. PubMed ID: 22929325
    [No Abstract]   [Full Text] [Related]  

  • 13. Pharmacovitrectomy.
    Dolz-Marco R; Gallego-Pinazo R; Díaz-Llopis M; Arévalo JF
    Dev Ophthalmol; 2014; 54():126-34. PubMed ID: 25196761
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and complications of ocriplasmin: ocriplasmin, ocriplasmin; oh, how safe art thou?
    Kim JE
    JAMA Ophthalmol; 2014 Apr; 132(4):379-80. PubMed ID: 24577332
    [No Abstract]   [Full Text] [Related]  

  • 15. Objective of pharmacologic vitreolysis.
    Gandorfer A
    Dev Ophthalmol; 2009; 44():1-6. PubMed ID: 19494646
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel possibility of vitreomacular traction treatment.
    Michalska-Małecka K; Witek K; Sierocka-Stępień J; Wyględowska-Promieńska D; Nowak M
    Acta Ophthalmol; 2016 Dec; 94(8):e818-e819. PubMed ID: 27167161
    [No Abstract]   [Full Text] [Related]  

  • 17. Pharmacologic Vitreolysis in Vascular Diseases of the Retina.
    Soliman MK; Agarwal A; Sarwar S; Hanout M; Sadiq MA; Do DV; Nguyen QD
    Ophthalmic Surg Lasers Imaging Retina; 2016 Jan; 47(1):60-8. PubMed ID: 26731211
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Understanding the adverse effects of ocriplasmin.
    Beebe DC
    JAMA Ophthalmol; 2015 Feb; 133(2):229. PubMed ID: 25376025
    [No Abstract]   [Full Text] [Related]  

  • 19. Vitreous as a substrate for vitreolysis.
    Bishop PN
    Dev Ophthalmol; 2009; 44():7-19. PubMed ID: 19494647
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Understanding the adverse effects of ocriplasmin - reply.
    Johnson MW; Fahim AT
    JAMA Ophthalmol; 2015 Feb; 133(2):230. PubMed ID: 25375273
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.